MX366405B - Uso de peptidos glp-1 de accion prolongada. - Google Patents

Uso de peptidos glp-1 de accion prolongada.

Info

Publication number
MX366405B
MX366405B MX2014014946A MX2014014946A MX366405B MX 366405 B MX366405 B MX 366405B MX 2014014946 A MX2014014946 A MX 2014014946A MX 2014014946 A MX2014014946 A MX 2014014946A MX 366405 B MX366405 B MX 366405B
Authority
MX
Mexico
Prior art keywords
peptides
long
acting glp
glp
acting
Prior art date
Application number
MX2014014946A
Other languages
English (en)
Other versions
MX2014014946A (es
Inventor
Bjørn Jensen Christine
Frederik Rasmussen Mads
Zdravkovic Milan
Kristensen Peter
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2014014946A publication Critical patent/MX2014014946A/es
Publication of MX366405B publication Critical patent/MX366405B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a uso de péptidos GLP-1 de acción prolongada en ciertos regímenes de dosificación para el tratamiento de diabetes tipo 2, obesidad, etc.
MX2014014946A 2012-07-01 2013-06-21 Uso de peptidos glp-1 de accion prolongada. MX366405B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12174535 2012-07-01
US201261694837P 2012-08-30 2012-08-30
US201261708162P 2012-10-01 2012-10-01
EP12186781 2012-10-01
PCT/EP2013/063004 WO2014005858A1 (en) 2012-07-01 2013-06-21 Use of long-acting glp-1 peptides

Publications (2)

Publication Number Publication Date
MX2014014946A MX2014014946A (es) 2015-04-08
MX366405B true MX366405B (es) 2019-07-08

Family

ID=65858459

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2019008148A MX376058B (es) 2012-07-01 2013-06-21 Uso de peptidos glp-1 de accion prolongada.
MX2014014946A MX366405B (es) 2012-07-01 2013-06-21 Uso de peptidos glp-1 de accion prolongada.
MX2020010693A MX2020010693A (es) 2012-07-01 2014-12-05 Uso de peptidos glp-1 de accion prolongada.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019008148A MX376058B (es) 2012-07-01 2013-06-21 Uso de peptidos glp-1 de accion prolongada.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020010693A MX2020010693A (es) 2012-07-01 2014-12-05 Uso de peptidos glp-1 de accion prolongada.

Country Status (17)

Country Link
US (2) US9764003B2 (es)
EP (3) EP2866825B1 (es)
JP (1) JP6059802B2 (es)
AU (3) AU2013286177B2 (es)
BR (1) BR112014032938A2 (es)
CA (1) CA2877056A1 (es)
DK (1) DK2866825T3 (es)
ES (2) ES3041720T3 (es)
HR (2) HRP20251088T1 (es)
HU (2) HUE049152T2 (es)
MX (3) MX376058B (es)
PL (2) PL3689365T3 (es)
PT (1) PT2866825T (es)
RS (2) RS60432B1 (es)
RU (2) RU2657573C2 (es)
SI (1) SI2866825T1 (es)
WO (1) WO2014005858A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
KR101972836B1 (ko) 2011-04-12 2019-04-29 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
EP2827885B1 (en) 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
HRP20251088T1 (hr) 2012-07-01 2025-11-07 Novo Nordisk A/S Upotreba dugodjelujućih peptida glp‑1
SMT201800492T1 (it) 2013-05-02 2018-11-09 Novo Nordisk As Dosaggio orale di composti di glp-1
US10543843B2 (en) * 2014-10-16 2020-01-28 Yanmar Co., Ltd. Work vehicle
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
DE102017106216A1 (de) * 2017-03-22 2018-09-27 Amw Gmbh Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung
TWI847306B (zh) 2017-08-24 2024-07-01 丹麥商諾佛 儂迪克股份有限公司 Ｇｌｐ-１組成物及其用途
IL322969A (en) * 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical therapy
GB201720187D0 (en) * 2017-12-04 2018-01-17 Imperial Innovations Ltd Novel Compounds
EP4299118A3 (en) 2018-02-02 2024-04-10 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
US20210162013A1 (en) * 2018-08-03 2021-06-03 Brown University Compositions and methods for improving the bioavailability of glp1 and analogues thereof
JP2022521551A (ja) * 2019-02-26 2022-04-08 ツイスト バイオサイエンス コーポレーション Ｇｌｐ１受容体の変異体核酸ライブラリ
EP3930757A1 (en) 2019-03-01 2022-01-05 President And Fellows Of Harvard College Methods and compositions for protein delivery
CN114728042A (zh) * 2019-11-06 2022-07-08 诺和诺德股份有限公司 用于痴呆的glp-1受体激动剂
CN119060162A (zh) * 2019-12-30 2024-12-03 甘李药业股份有限公司 长效glp-1化合物
TW202228762A (zh) 2020-01-30 2022-08-01 美商美國禮來大藥廠 提派肽(tirzepatide)之治療用途
BR112022013795A2 (pt) 2020-02-18 2022-09-13 Novo Nordisk As Composição farmacêutica líquida, e, kit
CN112768087A (zh) * 2020-12-23 2021-05-07 吉林大学 利用孟德尔随机化方法验证索马鲁肽口服制剂预防二型糖尿病的用途
EP4359074A4 (en) * 2021-06-24 2025-06-04 Gila Therapeutics, Inc. METHODS AND KITS FOR INDUCTING SATOURAGE AND TREATMENT OF METABOLIC DISEASES
US12514908B2 (en) 2021-07-05 2026-01-06 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
LT4408840T (lt) 2021-09-27 2025-10-10 Benzimidazolo karboksilinės rūgštys kaip glp-1r agonistai
WO2023076237A1 (en) 2021-10-25 2023-05-04 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
WO2023086499A1 (en) 2021-11-10 2023-05-19 I2O Therapeutics, Inc. Ionic liquid compositions
CN114621339B (zh) * 2021-12-28 2022-09-23 北京惠之衡生物科技有限公司 一种长效glp-1衍生物
JP2025508812A (ja) 2022-02-23 2025-04-10 ターンズ・ファーマシューティカルズ・インコーポレイテッド Ｇｌｐ－１ｒアゴニストとしての化合物
WO2023225370A1 (en) * 2022-05-19 2023-11-23 Vault Bioventures, Inc. Obesity treatment and prevention methods
AU2023415591A1 (en) 2022-12-30 2025-08-14 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
WO2024211898A1 (en) 2023-04-07 2024-10-10 Terns Pharmaceuticals, Inc. Combination comprising a thrbeta agonist anda glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease
AU2024299322A1 (en) 2023-07-24 2026-01-22 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for delivery of therapeutic peptides
WO2025165146A1 (ko) * 2024-01-29 2025-08-07 주식회사 티온랩테라퓨틱스 세마글루타이드 또는 티르제파타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용으로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법
KR102930984B1 (ko) * 2024-01-29 2026-02-25 주식회사 티온랩테라퓨틱스 세마글루타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법
WO2026046328A1 (en) * 2024-08-30 2026-03-05 Beijing Ql Biopharmaceutical Co., Ltd. Dosing regimen of glp-1 conjugates
CN118845644B (zh) * 2024-09-27 2025-01-17 杭州信海医药科技有限公司 一种司美格鲁肽注射液的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
EP1412384B1 (en) 2001-06-28 2007-12-26 Novo Nordisk A/S Stable formulation of modified glp-1
CA2539253A1 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
CN106137952B (zh) 2004-11-12 2020-11-17 诺和诺德公司 促胰岛素肽的稳定制剂
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
KR20150042304A (ko) 2006-04-14 2015-04-20 맨카인드 코포레이션 글루카곤 유사 펩타이드 1 （ｇｌｐ-1） 약제학적 제제
US20100047762A1 (en) 2007-03-20 2010-02-25 Nippon Kayaku Kabushiki Kaisha Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol
EP2164466A1 (en) 2007-06-01 2010-03-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
ES2672770T3 (es) 2007-09-05 2018-06-18 Novo Nordisk A/S Derivados del péptido-1 similar al glucagón y su uso farmacéutico
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
PL2373681T3 (pl) 2008-12-10 2017-07-31 Glaxosmithkline Llc Kompozycje farmaceutyczne albiglutydu
AU2010212823B2 (en) * 2009-02-13 2016-01-28 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
CN104327182B (zh) 2009-12-16 2020-04-17 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
KR101927068B1 (ko) * 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
CN103906528A (zh) 2011-06-24 2014-07-02 安米林药品有限责任公司 用glp-1受体激动剂的缓释制剂治疗糖尿病的方法
HRP20251088T1 (hr) 2012-07-01 2025-11-07 Novo Nordisk A/S Upotreba dugodjelujućih peptida glp‑1

Also Published As

Publication number Publication date
AU2020202573B2 (en) 2023-04-20
EP3689365A1 (en) 2020-08-05
MX2014014946A (es) 2015-04-08
HRP20200889T1 (hr) 2020-09-04
EP4406593A3 (en) 2024-10-23
PL3689365T3 (pl) 2025-11-12
EP2866825A1 (en) 2015-05-06
MX2020010693A (es) 2020-11-06
DK2866825T3 (da) 2020-06-08
JP6059802B2 (ja) 2017-01-11
AU2020202573A1 (en) 2020-05-07
EP3689365C0 (en) 2025-08-06
US20150190474A1 (en) 2015-07-09
AU2013286177A1 (en) 2015-01-15
ES2796839T3 (es) 2020-11-30
JP2015522573A (ja) 2015-08-06
HUE072859T2 (hu) 2025-12-28
MX2019008148A (es) 2019-09-05
AU2013286177B2 (en) 2018-04-26
PL2866825T3 (pl) 2021-02-22
ES3041720T3 (en) 2025-11-14
US9764003B2 (en) 2017-09-19
RS67258B1 (sr) 2025-10-31
US10335462B2 (en) 2019-07-02
RS60432B1 (sr) 2020-07-31
AU2018202504B2 (en) 2020-05-07
US20180085435A1 (en) 2018-03-29
MX376058B (es) 2025-03-07
CA2877056A1 (en) 2014-01-09
RU2018117557A3 (es) 2021-08-20
EP4406593A2 (en) 2024-07-31
PT2866825T (pt) 2020-07-15
RU2657573C2 (ru) 2018-06-14
EP3689365B1 (en) 2025-08-06
BR112014032938A2 (pt) 2017-08-01
WO2014005858A1 (en) 2014-01-09
EP2866825B1 (en) 2020-04-08
RU2015101826A (ru) 2016-08-20
HRP20251088T1 (hr) 2025-11-07
SI2866825T1 (sl) 2020-07-31
HUE049152T2 (hu) 2020-09-28
RU2018117557A (ru) 2019-03-22
AU2018202504A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
MX366405B (es) Uso de peptidos glp-1 de accion prolongada.
CL2021000008A1 (es) Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)
CY1121225T1 (el) Συμπυκνωμενες iμιδαζολυλιμιδαζολες ως αντιiκες ενωσεις
CY1120730T1 (el) Απο του στοματος χορηγουμενη δοσολογια ενωσεων glp-1
EA201490070A1 (ru) Коантагонисты глюкагонового рецептора/glp-1-рецептора
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
UA118558C2 (uk) Пептидна сполука
MX2013015168A (es) Co-agonista del receptor de glucagon/glp-1.
DK2728002T3 (da) Heterodimeriseret polypeptid
CL2015001699A1 (es) Compuestos derivados de nucleosidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y su uso para preparar un medicamento util en el tratamiento de la hepatitis c.
EA201690780A1 (ru) Пегилированные лекарственные средства-линкеры для улучшенной фармакокинетики конъюгатов лиганд-лекарственное средство
CL2013002001A1 (es) Uso de un agonista del receptor tipo toll para el tratamiento del cancer.
DK2940135T3 (da) Heterodimeriseret polypeptid
MX2016007063A (es) Peptidos terapeuticos.
CL2015001731A1 (es) Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
UY34859A (es) Análogos peptídicos de la exendina 4.
PE20151239A1 (es) Derivados de exendina-4 funcionalizada
PE20151178A1 (es) Analogos de glucagon
CL2014002556A1 (es) Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras.
CL2014001705A1 (es) Compuestos derivados de aza adamantano, inhibidores de 11beta-hsd-1; composicion farmaceutica; metodo para prevencion o tratamiento; y uso para prevenir o tratar el sindrome metabolico, diabetes tipo 2 como consecuencia de obesidad, resisitencia a insulina, dislipidemia, neuropatia, isquemia e infarto, entre otras enfermedades.
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
BR112015006692A2 (pt) formulação de nanodispersão, método para administrar uma formulação de nanodispersão líquida de taxina livre de etanol em um indivíduo, e, kit.
EA201490041A1 (ru) Пластырь, содержащий диклофенак и тиоколхикозид
TR201100150A2 (tr) Suda çözünür dozaj formları
MX377995B (es) Moléculas de unión al receptor bag3 para uso como un medicamento.

Legal Events

Date Code Title Description
FG Grant or registration